A Study of TYK-00540 in Adult Patients With Solid Tumors

NCT06246071 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2024-02-07

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety and tolerability of TYK-00540, with dose-escalation stage and dose-expansion stage.

Conditions

  • Locally Advanced or Metastatic Solid Tumors

Interventions

DRUG

TYK-00540

TYK-00540 PO, BID

Sponsors & Collaborators

  • TYK Medicines, Inc

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-02
Primary Completion
2026-12-05
Completion
2026-12-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06246071 on ClinicalTrials.gov